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Ranitidine is an antisecretory drug with H2 antagonist action useful in treating gastric and duodenal 
disorders. The dissolution test is used to obtain and compare dissolution profiles and establish similarities 
of pharmaceutical forms. The aim of this study was to compare the dissolution profiles of 150-mg coated 
ranitidine tablets of a reference drug (product A) and a generic (product B) and a similar (product C) 
drug marketed in Bahia, Brazil using a simple, fast and inexpensive ultraviolet method. Dissolution 
was determined using a USP type 2 apparatus at 50 rpm with 900 mL of distilled water at 37.0 ± 0.5 oC 
for 1h. The dissolution test was performed in compliance with the American Pharmacopoeia (USP‑32). 
Dissolution efficiency and difference (f1) and similarity (f2) factors were calculated and evaluated. The 
proposed quantification methodology for drug dissolution test was validated, presenting accuracy, linearity 
and precision within the acceptance criteria. Products A, B and C showed dissolution efficiency values 
of 59.29, 73.59 and 66.67%, respectively. Factors f1 and f2 were calculated and showed that the profiles 
of products A, B and C were dissimilar. However, all the products released ranitidine satisfactorily, with 
at least 80% of the drug dissolved within 30 min.
Uniterms: Ranitidine/coated tablets/dissolution test. Coated tablets/dissolution test. Spectrophotometry/
drug analysis.
A ranitidina é um fármaco antissecretor, antagonista H2, usado no tratamento de desordens gástricas e 
duodenais. O teste de dissolução é utilizado para obter e comparar perfis de dissolução, estabelecendo 
semelhança de formas farmacêuticas. Este estudo tem por objetivo comparar perfis de dissolução de 
comprimidos revestidos contendo 150 mg de ranitidina, em medicamentos de referência (produto 
A), genérico (produto B) e similar (produto C) comercializados na Bahia‑Brasil, usando um método 
ultravioleta simples, rápido e de baixo custo. As condições que permitiram a determinação da dissolução 
foram: aparelho USP tipo 2 a 50 rpm, contendo 900 mL de água destilada mantida a 37,0 ± 0,5 °C, 
durante 1 h. O teste de dissolução foi realizado em conformidade com a Farmacopeia Americana (USP‑
32). Cálculo da eficiência de dissolução e fatores de diferença (f1) e semelhança (f2) foram avaliados. A 
metodologia proposta para a quantificação do fármaco no ensaio de dissolução foi validada apresentando 
precisão, linearidade e exatidão dentro dos critérios de aceitação. Os produtos A, B e C mostraram 
eficiência de dissolução de 59,29, 73,59 e 66,67%, respectivamente. Calcularam-se os fatores f1 e f2 e 
mostrou-se que os perfis não foram semelhantes para os comprimidos de produtos A, B e C. No entanto, 
todos os produtos liberaram o fármaco satisfatoriamente, pois, pelo menos, 80% de ranitidina foram 
dissolvidos em 30 min.
Unitermos: Ranitidina/comprimidos revestidos/teste de dissolução. Comprimidos revestidos/teste de 
dissolução. Espectrofotometria/análise de fármacos.
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INTRODUCTION
Ranitidine is an antisecretory drug from the 
H2‑antagonist pharmacological class. It is used in the 
treatment of gastric and duodenal disorders, such as 
gastroesophageal reflux disease (GERD), gastritis, peptic 
ulcer disease, Zollinger‑Ellison, among others (Costa, 
2004; Mincis, Mincis, 2009; Xue et al., 2001; Grant et 
al., 1989; Moraes, 1999). It is well tolerated and rarely 
presents clinically significant drug interactions or serious 
adverse reactions, such as diarrhea, vertigo, muscle 
aches, transient cutaneous eruptions, hypergastrinemia, 
hepatic dysfunctions, reversible blood cell count changes, 
bradycardia, atrioventricular block and hypersensitivity 
reactions (urticaria, angioedema, bronchospasm and 
hypotension) (Holtz et al., 2007).
Ranitidine has a bioavailability of approximately 
50%. Seric concentrations between 300 and 500 ng mL‑1 are 
observable 2‑3 h after oral administration of 150 mg, with 
the maintenance of these levels for 6 to 8 h. About 6% of 
the dose is excreted in urine as N‑oxide, 2% as S‑oxide, and 
2% as desmethyl ranitidine, such as furoic acid analogues 
(Hoogerwerf, Pasricha, 2006). Ranitidine is highly soluble 
in water and little cell membrane permeable (Coelho, 
2007), being classified as a class III drug according to the 
Biopharmaceutical Classification System (BCS) proposed 
by the Food and Drug Administration (FDA). Only Class 
I (high solubility and high permeability) and some Class 
III (high solubility and low permeability) drugs can be 
assessed for bioequivalence by dissolution test alone 
(Bonamici, 2009).
Currently, monitoring the quality of pharmaceutical 
solid oral dosage forms (capsules and tablets) has gained 
greater importance to pharmaceutical companies and 
regulatory authorities. In Brazil, several drugs are 
commercially available, such as reference, similar and 
generic drugs. Both similar and generic drugs must have 
proven pharmaceutical equivalence to their reference drug. 
Therefore, profiling and comparison of drug dissolution is 
a requirement (Brasil, 2007a,b).
One of the required pharmaceutical equivalence 
tests is the comparison of drug dissolution profiles 
to that of a reference drug. “The dissolution test is 
currently used as an in vitro bioequivalence (BE) test, 
generally for dissolution profile and profile comparison, 
establishing the similarity of pharmaceutical dosage 
forms” (Menegola, Steppe, Schapoval, 2007). An ideal 
dissolution test must provide product quality information 
as well as some preliminary in vivo/in vitro correlation or 
biorelevance (Emani, 2006). Therefore, the dissolution 
test can contribute to the continued evaluation and 
monitoring of products and the development of new 
formulations (Ferraz et al., 2005).
Mathematical and statistical methods can be used 
to evaluate the similarity of drug dissolution profiles. 
Equations f1 and f2 and Rescigno index are mathematical 
models used to compare dissolution profiles and one-way 
ANOVA, two-way ANOVA and Chow and Ki are the 
main statistical methods used. However, the Food and 
Drug Administration (FDA) recommends only equations 
f1 and f2 (O’Hara et al., 1998). Drug dissolution profiles 
may be distinct due to differences in formulations and 
manufacturing processes, but the differences must not 
compromise product bioequivalence (Storpirtis et al., 
1999).
While a growing number of studies have investigated 
the dissolution profiles of oral dosage drug solid forms, 
the dissolution kinetics of coated ranitidine tablets remains 
unexplored (Ferraz et al., 2005; Brundusino, Pinto Coelho, 
Oliani, 1999; Shen, Lee, McKeag, 1995; Alkaysi et al., 
1989).
This study aims to compare the dissolution profiles 
of 150‑mg ranitidine coated tablets of reference, generic 
and similar drugs marketed in Bahia, Brazil using a simple, 
fast and inexpensive ultraviolet method.
MATERIAL AND METHODS
Material
All chemicals used were of analytical grade. Double 
distilled water was used throughout the experiments. 
Laboratory glassware was kept in a 10% v/v nitric acid 
solution overnight and rinsed with deionized water and 
dried in a dust‑free environment before use. Reference 
ranitidine hydrochloride was obtained from Sigma‑Aldrich 
(USA), whereas ranitidine pharmaceutical formulations 
were purchased from local drugstores. A ranitidine 
solution with final concentration of 17.00 mg mL‑1 was 
used to obtain the ranitidine standard curve. Ten aqueous 
solutions of ranitidine standard were prepared with 
concentrations ranging from 1.0 to 30.0 µg mL‑1 and 
analyzed in triplicate by UV spectrophotometry at 314 nm. 
Water was purified using a Millipore® system.
The ranitidine tablets used in the dissolution test and 
for profile comparison were:
Product A
(Reference product) – drug label content of 
150 mg and the following excipients: microcrystalline 
cellulose, magnesium stearate and Opadry OU‑S‑7322 
(hypromellose, titanium dioxide and triacetin).
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Product B
(Generic product) – drug label content of 150 mg 
and the following excipients: microcrystalline cellulose, 
magnesium stearate, povidone, colloidal silicon dioxide, 
croscarmellose sodium, hypromellose, polyethylene 
glycol, titanium dioxide and ethyl alcohol)
Product C
(Similar product) – drug label content of 150 mg 
and the following excipients: microcrystalline cellulose, 
lactose, magnesium stearate, colloidal silicon dioxide, 
croscarmellose sodium, hypromellose, polyethylene 
glycol, titanium dioxide and ethylcellulose.
The coated ranitidine tablets were submitted to 
average weight, friability, disintegration and dissolution 
tests following the Brazilian Pharmacopoeia general 
methods applied to drugs.
Instrumentation
Ranitidine coated tablets were submitted to average 
weight, disintegration and dissolution tests following the 
official compendia. An electronic balance (Sartorius), a 
UV spectrophotometer (Varian model CARY 100 Bio, 
Australia), a disintegration test apparatus Nova Ética 
(Model 301/AC 01, Brazil) and a dissolution test apparatus 
Nova Ética (Model 299, Brazil) multi-bath (n = 6) were 
used in accordance with the United States Pharmacopoeia 
(USP 32) general methods.
Dissolution test conditions
Dissolution tests were performed in compliance 
with USP‑32 (USP, 2009) using an apparatus 2 (paddles) 
at 50 rpm and 900 mL of dissolution medium (distilled 
water) at 37.0 ± 0.5 oC for 1 h. Manual sampling aliquots of 
10.0 mL were taken at 5, 10, 15, 20, 30, 40, 50 and 60 min 
after dissolution optimization and analyzed. The medium 
was replaced at 37 ± 0.5 °C to a constant volume. The 
collected aliquots were filtered and transferred to amber 
vials for subsequent UV spectrophotometry reading (Varian 
model CARY 100 Bio) at 314 nm. The standard solution 
used in all dissolution tests was prepared from an amount 
of ranitidine transferred to a 50-mL volumetric flask with 
the dissolution medium (17.0 mg mL‑1). The absorbency 
values were converted to concentrations values with the 
standard curve equation taking into account the amount of 
drug removed in each aliquoting; the results were expressed 
as percentage as a function of time.
In this study, the independent model simple 
method employing the difference (f1) and similarity (f2) 
factors was used to compare the dissolution profiles, 
in accordance with Resolution 31/2010 of the National 
Sanitary Surveillance Agency (Agência Nacional de 
Vigilância Sanitária, ANVISA) (Brasil, 2010b). Factor 
f1 indicates the percentage difference (dissimilarity) 
between two dissolution profiles; f2 is the logarithm of the 
reciprocal square root transformation of the sum squared 
error. It indicates the average percentage of similarity 
between two dissolution profiles. Acceptable f1 values are 
between 0 and 15, while f2 values are between 50 and 100. 
An f1 value over 15 indicates significant dissimilarity and 
an f2 value over 50, significant similarity (Gupta, Gaud, 
Srinivasan, 2010).
Dissolution Efficiency (DE)
The DE was obtained from the area under the drug 
dissolution curve (AUC) up to time t in minutes in relation 
to 100% of the product label value (Banakar, 1992; 
Moore, Flanner, 1996; Costa, Sousa Lobo, 2001). The 
DE was determined as the ratio between the area under 
the dissolution curve of ranitidine for the time interval 
from zero to 60 min (AUC 0‑60 min) and the total area of 
the rectangle (ASCTR) was defined by the ordinate (100% 
dissolution) and the abscissa (time equal to 60 min). The 
efficiency of dissolution is not comparative parameter of 
dissolution kinetics, but a parameter which characterizes 
drug release. The DE% results of the tested products were 
submitted to variance analysis (ANOVA). 
Validation of the analytical method
In order to demonstrate whether the dissolution test 
method was adequate, it was validated following ANVISA 
Resolution Nº 899 (Brasil, 2003). Thus, linearity, precision 
(repeatability and intermediate precision) and accuracy 
were assessed.
The linearity was obtained through the correlation 
coefficient of three standard curves with ten different 
aqueous solutions concentrations from 1.0 to 30.0 µg mL‑1. 
Solutions with concentrations of 1.0, 15.0 and 30.0 µg mL‑1 
were prepared for triplicate study of precision and 
accuracy. Aliquots of a 17.0‑mg mL‑1 solution of ranitidine 
reference standard were prepared with distilled water 
and transferred to volumetric flasks to obtain the final 
concentrations; absorbance was determined at 314 nm. 
Linearity was evaluated by linear regression analysis using 
the least squares regression method.
Repeatability and intermediate precision were used 
to assess the precision of the method. Relative standard 
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deviation (RSD) was used to calculate the precision of 
quantification of three known concentrations of ranitidine 
(1.0, 15.0 and 30.0 µg mL‑1) on the same and on alternate 
days. Each concentration was prepared in duplicate and 
analyzed in triplicate in a UV‑VIS spectrophotometer on 
two consecutive days in the same spectrophotometer by 
the same operator.
Accuracy was expressed as the agreement between 
the set reference value and the measured value of 
each concentration. Each concentration (1.0, 15.0 and 
30.0 µg mL‑1) was analyzed in triplicate in a UV‑VIS 
spectrophotometer.
RESULTS AND DISCUSSION
To assess the method linearity, calibration curves of 
ranitidine concentration (μg mL‑1) versus absorbance were 
plotted, giving a correlation coefficient of approximately 
0.9997 in the concentration range studied (1.0 to 
30.0 µg mL‑1). The representative linear equation was 
y = 0.0472x - 0.0293. The data were validated by analysis 
of variance (ANOVA) and presented significant linear 
regression and no significant linearity deviation (p<0.05) 
(Brasil, 2010b). Ranitidine concentration measurement 
Accuracy was determined by same‑ (intraday) and 
alternate‑day (interday) spectrophotometry in dissolution 
test standardized conditions. The average recovery was 
obtained in the range from 96.50 to 102.87%. The relative 
standard deviation (RSD) values were less than 5%, 
considering the dissolution procedure and analysis method 
precision satisfactory.
Dissolution profile analysis is an important tool to 
evaluate formulation development and finished products, 
for batch quality control and establishing the similarity 
between a generic formulation and its reference product 
(Marcolongo, 2009). Simultaneous assessment of the 
chemical and physical characteristics of the excipients 
present in the analyzed product is critical to justify 
possible variations in tablet mass as well as in friability, 
disintegration and dissolution results (Rowe, Sheskey, 
Quinn, 2009; Gil, Brandão, 2007).
The immediate release tablet coating does not 
significantly alter the drug release kinetics of its dosage 
form. The coating components basically confer protection 
to the coated material, facilitate swallowing or mask 
unpleasant tastes (Rowe, Sheskey, Quinn, 2009; Gil, 
Brandão, 2007). The coating compounds of the tested 
products are a film-forming agent, a plasticizing agent 
and an opacifier agent. Products A, B and C are coated 
with the same film‑forming agent and opacifier agent, 
hypromellose and titanium dioxide, respectively. Product 
A uses triacetin as a plasticizer and products B and C use 
polyethylene glycol. 
Products A and B use only microcrystalline 
cellulose as a formulation diluent, while Product C 
uses lactose, which are water insoluble and soluble, 
respectively. Lactose gives the tablet a more homogeneous 
appearance, since microcrystalline cellulose has diluting 
and disintegrating functions. All the products use 
magnesium stearate as a lubricant, which can hinder 
drug interaction with biological fluids and, therefore, 
interfere with its release. Only product B uses povidone 
as a binder. Silicon dioxide, a sliding agent, facilitates the 
flow of powder through machinery. Formulations B and 
C use croscarmellose sodium as a disintegrating agent, 
facilitating the release of the drug for absorption (Rowe, 
Sheskey, Quinn, 2009; Gil, Brandão, 2007).
The results showed that drugs A, B and C have 
satisfactory average weight values (Figure 1) according to 
the American Pharmacopoeia (USP‑32). Product B tablets 
are more uniform and have a lower coefficient of variation 
than products A and C.
 
The tested products had satisfactory disintegration 
results. All samples disintegrated within 4 to 10 min. 
Therefore, all samples met the official compendium 
requirement of 30‑min dissolution. Products B and 
C disintegrated faster, possibly due to the presence 
of disintegrating agents croscarmellose sodium and 
microcrystalline cellulose. Lactose, used in product C, 
may also have favored disintegration.
The Brazilian Pharmacopoeia (Brasil, 2010a) 
recommends that not less than 80% of the ranitidine label 
amount (150 mg) must dissolve within 45 min. Several 
factors may influence dissolution results, such as the 
nature of the excipients and coating used and the rate of 
FIGURE 1 ‑ Average weight of coated tablets of products A, B 
and C.
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disintegration. Figure 2 gives the levels of ranitidine in the 
dissolution media at 45 min.
All products were analyzed according to the official 
compendium recommendations. Products A and C showed 
comparable levels in the studied time frame. This suggests 
that the active principle from coated tablets of products A 
and C dissolves proportionally to time in water. However, 
dissolution kinetics calculations are required to verify 
which model matches the profiles obtained.
Dissolution time analysis, proposed by the Brazilian 
Pharmacopoeia (Brasil, 2010a), is punctual and provides 
few dissolution process data. Therefore, to understand 
how the pharmaceutical form releases the drug over time, 
multipoint analysis is essential. Multipoint analysis graphs 
were plotted to evaluate the amount of the drug dissolved 
versus time (Figure 3).
Since the dissolution profiles for 20 min of analysis 
were similar, visual analysis was performed to determine 
TABLE I ‑ Factors f1 and f2 of products A, B and C
Comparison f 1 f 2
Product A x Product B 26.52 39.00
Product A x Product C 17.02 43.23
Product B x Product C 8.12 49.45
FIGURE 2 ‑ Ranitidine dissolved from coated tablets (150 mg) 
of products A, B and C within 45 min.
FIGURE 3 - Dissolution profiles of ranitidine coated tablets 
(150 mg) of products A, B and C. (USP type 2 apparatus at 
50 rpm with 900 mL distilled water at 37.0 ± 0.5 oC for 1).
which product released the active principle the soonest. 
After 20 min, the release from product C stabilized, while 
that of product B continued with the ensuing increase in the 
concentration of ranitidine in the medium until it stabilized 
after 30 min of test. This concentration was significantly 
higher than those of the other products. After 30 min, 
the dissolution profiles of products A and C practically 
superimposed, indicating similar drug dissolution until the 
end of the test. Product C had a dissolution profile similar 
to the other two products, differing only in the dissolution 
time. It resembled that of the product B from 0 to 20 min 
and that of product A from 30 to 60 min. 
The analysis of the dissolution profiles of products 
A, B and C showed a difference in the release of ranitidine 
in the first 10 min, especially for product A, which may 
have been related to the product formulation, as it does not 
use croscarmellose sodium as a disintegrant.
In order to compare the dissolution profiles, 
mathematical methods, equations f1 (difference factor) 
and f2 (similarity factor), were used. Factors f1 and f2 
were calculated according to the criteria in the literature 
(Brasil, 2010b). The results are given in Table I.
Factors f1 and f2 were different and below the 
requirements for products B and C when compared 
to product A, with better results for product C. The 
dissolution profiles of products B and C were very close to 
the recommendations. The difference factor (f1) gives the 
percentage difference between two curves at each reading 
time and is a measure of the relative error between the 
two curves. On the other hand, the similarity factor (f2) is 
the most appropriate method to compare release profiles. 
The difference factor (f1) gave values within the specified 
limits and the similarity factor (f2) was very close to the 
acceptance limit (49.45). The comparison of dissolution 
profiles using f1 and f2 is easy to understand, gives reliable 
results, also being widespread and the most recommended 
method by the FDA (FDA, 1997). 
Ranitidine release from coated tablets was also 
assessed through dissolution efficiency (DE). If a drug has 
high dissolution efficiency, one can infer that the active 
principle remains in contact with physiologic membranes 
for a long time and, thus, has a great bioavailability in the 
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assessed concentration range. The equations of f1 and 
f2 were used to compare the formulations under study. 
Products A, B and C had dissolution efficiency values 
of 59.29, 73.59 and 66.67%, respectively. The analysis 
of variance (ANOVA) revealed a statistical difference 
(p<0.05) between the products. Differences in the DE data 
may be related to the dissolution profiles of the products, 
since factors such as tablet coating (film), polymorphism 
and biopharmaceutical factors may influence the release 
of the active principle.
This analysis allowed us to evaluate the actual 
amount of drug dissolved in the medium, which is 
indicative of a better in vivo test result, considering that 
drug bioavailability depends exclusively on the amount of 
drug dissolved in the enteric medium.
CONCLUSIONS
Ranitidine is classified as a Class III drug (high 
solubility and low permeability) by the BCS. Dissolution 
tests are essential for the prognosis of dosage form oral 
absorption and bioequivalence of drugs. Ranitidine samples 
were analyzed using a validated UV spectrophotometric 
method. The method validation showed that the dissolution 
test is suitable for the quantification of ranitidine in 
coated tablet pharmaceutical form in in vitro studies with 
linearity, precision and accuracy.
The tested products (reference, similar and generic 
drugs) had a satisfactory average weight and disintegration 
results. The dissolution profiles were compared with the 
use of dissolution efficiency and factors f1 and f2, showing 
that product A, B and C tablets were dissimilar. Drug 
release was satisfactory for all products, since at least 80% 
of the ranitidine was dissolved in the medium within 30 
min of the test.
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